A detailed history of Ubs Group Ag transactions in Forte Biosciences, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 33 shares of FBRX stock, worth $19. This represents 0.0% of its overall portfolio holdings.

Number of Shares
33
Previous 146 77.4%
Holding current value
$19
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 13, 2024

SELL
$0.48 - $0.85 $54 - $96
-113 Reduced 77.4%
33 $0
Q4 2023

Feb 09, 2024

SELL
$0.38 - $0.82 $883 - $1,906
-2,325 Reduced 94.09%
146 $0
Q3 2023

Nov 09, 2023

BUY
$0.65 - $1.04 $1,584 - $2,535
2,438 Added 7387.88%
2,471 $1,000
Q2 2023

Aug 11, 2023

SELL
$0.98 - $1.11 $9,297 - $10,530
-9,487 Reduced 99.65%
33 $0
Q1 2023

May 12, 2023

BUY
$0.98 - $1.06 $7,648 - $8,273
7,805 Added 455.1%
9,520 $9,000
Q4 2022

Feb 08, 2023

BUY
$0.96 - $1.04 $1,614 - $1,749
1,682 Added 5096.97%
1,715 $1,000
Q3 2022

Nov 10, 2022

SELL
$1.06 - $1.53 $1,970 - $2,844
-1,859 Reduced 98.26%
33 $0
Q2 2022

Aug 10, 2022

SELL
$1.07 - $1.55 $298 - $432
-279 Reduced 12.85%
1,892 $2,000
Q1 2022

May 16, 2022

SELL
$1.21 - $2.24 $11,306 - $20,930
-9,344 Reduced 81.15%
2,171 $3,000
Q4 2021

Feb 14, 2022

BUY
$2.02 - $3.36 $22,654 - $37,682
11,215 Added 3738.33%
11,515 $25,000
Q3 2021

Nov 15, 2021

SELL
$2.96 - $36.67 $953 - $11,807
-322 Reduced 51.77%
300 $1,000
Q2 2021

Aug 13, 2021

BUY
$31.5 - $42.5 $10,143 - $13,685
322 Added 107.33%
622 $21,000
Q1 2021

May 12, 2021

SELL
$25.01 - $40.24 $10,004 - $16,096
-400 Reduced 57.14%
300 $10,000
Q4 2020

Feb 11, 2021

BUY
$28.66 - $46.79 $515 - $842
18 Added 2.64%
700 $26,000
Q3 2020

Nov 12, 2020

BUY
$14.71 - $50.69 $10,032 - $34,570
682 New
682 $34,000

Others Institutions Holding FBRX

About Forte Biosciences, Inc.


  • Ticker FBRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 20,340,300
  • Market Cap $12M
  • Description
  • Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. It is developing FB-102 program that addresses various autoimmune diseases, such as vitiligo and alopecia areata. The company is headquartered in Dallas, Texas.
More about FBRX
Track This Portfolio

Track Ubs Group Ag Portfolio

Follow Ubs Group Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.